期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 15, 期 9, 页码 1007-1017出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1081566
关键词
androgen receptor inhibitors; castration resistant; efficacy; metastatic; non-metastatic; ODM-201; pharmacodynamics; pharmacokinetics; prostate cancer; tolerability
类别
资金
- Orion Pharma
Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据